# Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®

> **NCT03287128** · — · UNKNOWN · sponsor: **Versailles Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin (GO)

## Key facts

- **NCT ID:** NCT03287128
- **Lead sponsor:** Versailles Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-01
- **Primary completion:** 2018-10-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287128, "Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03287128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*